Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Shire Plc Acquires Lotus Tissue Repair Inc


Tuesday, 8 Jan 2013 07:00am EST 

Shire Plc announced that it has signed an agreement to acquire Lotus Tissue Repair Inc of Cambridge MA, a privately held biotechnology company developing the protein replacement therapy being investigated for the treatment of dystrophic epidermolysis bullosa (DEB). Shire will purchase the Company for an upfront payment and certain contingent payments based on the achievement of certain safety and development milestones. Financial terms of the transaction were not disclosed. 

Company Quote

146.78
2.38 +1.65%
16 Apr 2014